Precision Biologics Highlights New AML Target for CAR-NK Therapies

US-based Precision Biologics, a clinical stage biotechnology company, has announced new preclinical findings identifying a potential therapeutic target for acute myeloid leukemia (AML), which the company will present at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, Calif. The study highlights ongoing efforts to expand antigen discovery for cell-based immunotherapies, according to a company announcement on April 17, 2026.